Product Description
Simnova Biotechnology is developing CART-BCMA as a treatment for multiple myeloma. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05346198)
Mechanisms of Action: CAR-T,BCMA
Novel Mechanism: No
Modality: Cell Therapy
Route of Administration: Oral
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Synchroneuron
Company Location:
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China
Active Clinical Trial Count: 2
Highest Development Phases
Phase 2: Multiple Myeloma
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| B03B00301-101 | P1 |
Active, not recruiting |
Multiple Myeloma |
2022-07-31 |
44% |
| CTR20230238 | P2 |
Not yet recruiting |
Multiple Myeloma |
None |